TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7840430
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (daily alcohol intake < 40 g)
Study: 2628537
Drug: Adrenaline 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.01 mg/kg
Study: 2628537
Drug: Salbutamol 0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.007 mg/kg
Study: 31823057
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of paracetamol, anti-neuropathic pain drugs, and opioids in the intervention group
Study: 30205020
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in group O (osteoporosis)
Study: 30205020
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in group C (control)
Study: 25738212
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d) plus Vitamin D3 placebo
Study: 21872439
Drug: Non-statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin treatment (Control)
Study: 19570393
Drug: Insulin added
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin added into 'all in one' bags
Study: 19570393
Drug: Insulin added
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin added into syringes and transfused by infusion pump
Study: 15995106
Drug: Bacitracin solution
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacitracin solution (group B)
Study: 15995106
Drug: Castile soap
Normalized name: CASTILE SOAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castile soap solution (group C)
Study: 11604622
Drug: 5-fluorouracil solution
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil solution for 5 minutes after excision
Study: 29578578
Drug: Sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 100 mg every 2 weeks
Study: 23756581
Drug: Grana Padano
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grana Padano cheese containing lysozyme (30 g)
Study: 23756581
Drug: TrentinGrana cheese
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TrentinGrana cheese (lysozyme-free, 30 g)
Study: 2213803
Drug: Automated External
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated External Defibrillator (AED) as an adjunct to basic life support
Study: 619237
Drug: Leg injection
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg injection
Study: 619237
Drug: Abdominal injection
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal injection
Study: 28858080
Drug: Acarbose +
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose + insulin
Study: 28858080
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + insulin
Study: 10393618
Drug: L-amino acid-based
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-amino acid-based elemental formula (AAF)
Study: 1909274
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of Intron‐A trice weekly for 6 months (Group A)
Study: 1909274
Drug: Dose titration
Normalized name: Rebif Rebidose Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration according to ALT-AST values (Group B)
Study: 1909274
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: no treatment for 6 months (Group D)
Study: 6636797
Drug: Euphyllin retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphyllin retard 350 mg
Study: 6636797
Drug: Mundiphyllin retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mundiphyllin retard 225 mg
Study: 6636797
Drug: Intravenous Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Theophylline (10 mg/kg body weight over 24 hours)
Study: 31287010
Drug: Mindful-compassion art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful-compassion art therapy (MCAT)
Study: 25412293
Drug: Injected placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected placebo (OxyRBX) - subcutaneous saline injections daily during the placebo phase
Study: 18303488
Drug: Bexarotene (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexarotene (75 mg/d)
Study: 15271195
Drug: Ciclopirox 1%
Normalized name: Ciclopirox 1% Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 1% shampoo applied once weekly
Study: 15271195
Drug: Ciclopirox 1%
Normalized name: Ciclopirox 1% Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 1% shampoo applied twice weekly
Study: 15271195
Drug: Ciclopirox 1%
Normalized name: Ciclopirox 1% Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopirox 1% shampoo applied three times weekly
Study: 7995184
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei strain GG 10(10) colony-forming units twice daily for five days
Study: 3135047
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of adrenaline
Study: 29871798
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz rTMS administered over the right parietal lobe for 10 days
Study: 27018305
Drug: Assisted Cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted Cycling Therapy (ACT)
Study: 16041840
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (100-300 mg per day for 4 weeks)
Study: 7818104
Drug: Ketorolac (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (1 mg/kg)
Study: 7818104
Drug: Acetaminophen (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (35 mg/kg)
Study: 6345178
Drug: Prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1 mg twice daily)
Study: 6345178
Drug: Prazosin (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (highest tolerated dose 2-8 mg daily)
Study: 31200437
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein (HP, n = 22) - 1.2 g protein·kg‐1·d‐1
Study: 31200437
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein (NP, n = 25) - 0.8 g protein·kg‐1·d‐1
Study: 30045757
Drug: Medication monitor-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication monitor-based treatment strategy
Study: 24461395
Drug: On-demand ibuprofen
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand ibuprofen (400 mg single dose plus rescue medication)
Study: 24461395
Drug: Regular ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular ibuprofen (400 mg every 6 hours for at least 24 hours)
Study: 22033897
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of hyaluronic acid (HA) and contrast dye
Study: 22033897
Drug: Blind injection
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injection of hyaluronic acid (HA) and contrast dye
Study: 19084273
Drug: Travatan Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travatan Dosing Aid (DA; Alcon, Fort Worth, TX)
Study: 17932361
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of folic acid plus 5 mg of riboflavin
Study: 15754276
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (250 mg/wk, subsequently increased to 500 mg/wk)
Study: 15754276
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (500 mg/wk)
Study: 15754276
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (250 mg/wk and 500 mg/wk)
Study: 15754276
Drug: Intravenous ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbate (during supplementation)
Study: 12401606
Drug: Hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric lidocaine 25 mg with fentanyl 20 microg (n = 37)
Study: 12401606
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 4 mg with fentanyl 20 microg (n = 35)
Study: 10190377
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg twice daily for 3 days
Study: 10190377
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg twice daily for 3 days
Study: 10190377
Drug: Trimethoprim/sulfamethoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole 160/800 mg twice daily for 3 days
Study: 7549296
Drug: Hypo-osmolar ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar ORS containing L-alanine and glucose (osmolality 255 mosmol/l)
Study: 7549296
Drug: WHO-ORS (osmolality
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO-ORS (osmolality 311 mosmol/l)
Study: 7549296
Drug: i.v. polyelectrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. polyelectrolyte solutions (osmolality 293 mosmol/l)
Study: 18294410
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 100 mg
Study: 15777304
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine plus ketorolac (K group)
Study: 15777304
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA morphine (M group)
Study: 12007762
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg or 30 mg)
Study: 10715786
Drug: EVL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVL treatment
Study: 7767523
Drug: NPPV (noninvasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV (noninvasive positive pressure ventilation) administered by nasal mask connected to a BiPAP device
Study: 7767523
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (control)
Study: 31755959
Drug: Unconventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconventional treatment (more than two lines)
Study: 17259059
Drug: Greater intercourse
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater intercourse frequency and pill use
Study: 15115249
Drug: Standard clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clamp (insulin‐infusion rate 30 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Study: 15115249
Drug: Hyperinsulinaemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Study: 15115249
Drug: Hyperinsulinaemic, hyperglycaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinaemic, hyperglycaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 12.0 mmol/L)
Study: 11257150
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and pulse cyclophosphamide (0.7 g/m2 at diagnosis) followed by either pulse or oral cyclophosphamide (2 mg/kg/day)
Study: 11257150
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and cyclophosphamide treatment
Study: 9481149
Drug: Computerized version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computerized version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Study: 9481149
Drug: Paper and
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper and pencil version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Study: 25002833
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (nutrition support commenced via gastrostomy when clinically indicated during treatment)
Study: 22897671
Drug: Synthetic gel
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic gel model
Study: 20485955
Drug: Hypobaric 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric 0.15% bupivacaine (3 mL, 4.5 mg)
Study: 20485955
Drug: Hypobaric 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric 0.6% lidocaine (3 mL, 18 mg)
Study: 12871461
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin E at 900 IU day(-1), vitamin C at 2000 mg day(-1)) for 6 weeks
Study: 12871461
Drug: Anti-beta(2) glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-beta(2) glycoprotein 1 (beta(2)GP(1)) antibodies
Study: 8571024
Drug: Low-dose hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormonal contraceptive (gestodene 75 mcg + ethinylestradiol 30 mcg)
Study: 25455039
Drug: Symbiotic gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin)
Study: 16534049
Drug: Single-dose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (1 g) oral azithromycin
Study: 16534049
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin for household members (20 mg/kg up to 1 g) plus the patient
Study: 22159169
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (twice per day for 6 weeks)
Study: 10673249
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg/d for 1 month
Study: 1790067
Drug: Josamycin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (750 mg/12 h/orally)
Study: 1790067
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (500 mg/8 h)
Study: 28719717
Drug: Sildenafil (Viagra)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil (Viagra) at 50 mg twice a week for 3 weeks
Study: 28719717
Drug: Tadalafil (Cialis)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil (Cialis) at 20 mg twice a week for 3 weeks
Study: 28719717
Drug: Vardenafil (Levitra)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil (Levitra) at 20 mg twice a week for 3 weeks
Study: 24558764
Drug: Land-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based exercise therapy
Study: 19244540
Drug: Sulpiride (D(2)
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (D(2) antagonist)
Study: 19244540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulpiride and L-dopa
Study: 15637825
Drug: Self‐administered survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered survey
Study: 30192928
Drug: Low-dose scopolamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose scopolamine (0.2 mg IV)
Study: 27492015
Drug: Irinotecan 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 110 mg/m2 on day 1 and 100 mg/m2 on day 8 plus cisplatin 80 mg/m2 on day 8 every 3 weeks (IC arm)
Study: 27492015
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus cisplatin 80 mg/m2 on day 1 every 3 weeks (PC arm)
Study: 25475357
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg in divided doses)
Study: 14662281
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.5 mg respectively)
Study: 8957972
Drug: 0.25% caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% caudal bupivacaine 0.5 ml kg‐1 and diamorphine 30 micrograms kg‐1
Study: 8957972
Drug: 0.25% caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% caudal bupivacaine 0.5 ml kg‐1 alone
Study: 3911482
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) initial dose 240 U (anti F Xa)/kg/12 h in study I; 120 U (anti F Xa)/kg/12 h in study II
Study: 3911482
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) initial dose 240 U/kg/12 h in both studies
Study: 16873380
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 40 mg and 80 mg doses
Study: 16271643
Drug: Metoprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (up to 15 mg intravenous then 200 mg oral daily; n=22,929)
Study: 2404480
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg/d for 14 days
Study: 334227
Drug: Nomifensine (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (50-200 mg daily)
Study: 334227
Drug: Amitriptyline (50-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-225 mg daily)
Study: 30770291
Drug: Standard radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiotherapy - 66 Gy in 33 daily 2 Gy fractions or 50 Gy in 20 daily 2.5 Gy fractions, depending on institutional preference.
Study: 24036915
Drug: Visual stimuli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual stimuli designed to elicit variable V1 response spread, details on dosage and duration not available.
Study: 18830816
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Tamoxifen
Study: 18323331
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg, twice daily (BID)
Study: 3420976
Drug: FBKC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBKC vaccine
Study: 3420976
Drug: PCEC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEC vaccine
Study: 3420976
Drug: PVRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV vaccine
Study: 24341101
Drug: Shuganyiyang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuganyiyang Capsule combined with tamsulosin hydrochloride sustained release tablets and prostat tablets
Study: 16080273
Drug: rizatriptan capsule
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rizatriptan capsule preparation (test)
Study: 16080273
Drug: rizatriptan tablet
Normalized name: rizatriptan Oral Tablet
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rizatriptan tablet (reference)
Study: 8949806
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1
Study: 8949806
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1
Study: 8949806
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 with propofol 2.5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Study: 8949806
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 with thiopentone 5 mg kg‐1 and alfentanil 20 micrograms kg‐1
Study: 1921398
Drug: Combined application
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil
Study: 1921398
Drug: IHA chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHA chemotherapy with the same chemotherapeutic regimen
Study: 17514537
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (T1): 2,092 kJ/day (500 kcal/day) peanuts for 8 weeks
Study: 17514537
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (T2): 2,092 kJ/day (500 kcal/day) peanuts for 3 weeks
Study: 17514537
Drug: Treatment 3
Normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3 (T3): Substitution of 2,092 kJ/day fat with energy from peanuts